These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23952052)

  • 21. Influence of nanostructured lipid carriers (NLC) on the physical properties of the Cutanova Nanorepair Q10 cream and the in vivo skin hydration effect.
    Pardeike J; Schwabe K; Müller RH
    Int J Pharm; 2010 Aug; 396(1-2):166-73. PubMed ID: 20541000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blunted epidermal L-tryptophan metabolism in vitiligo affects immune response and ROS scavenging by Fenton chemistry, part 2: Epidermal H2O2/ONOO(-)-mediated stress in vitiligo hampers indoleamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immune response signaling.
    Schallreuter KU; Salem MA; Gibbons NC; Maitland DJ; Marsch E; Elwary SM; Healey AR
    FASEB J; 2012 Jun; 26(6):2471-85. PubMed ID: 22415306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progressive facial hyperpigmentation].
    Blumeyer A; Röwert-Huber J; Nast A; Reidel U
    Hautarzt; 2016 Nov; 67(11):922-924. PubMed ID: 27393085
    [No Abstract]   [Full Text] [Related]  

  • 24. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
    Majid I
    Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular evidence that halo in Sutton's naevus is not vitiligo.
    Schallreuter KU; Kothari S; Elwary S; Rokos H; Hasse S; Panske A
    Arch Dermatol Res; 2003 Nov; 295(6):223-8. PubMed ID: 14530988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
    Bakis-Petsoglou S; Le Guay JL; Wittal R
    Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitiligo: a potential autoimmune sequela of DRESS syndrome.
    Lonowski S; Hau J; Worswick S
    Br J Dermatol; 2016 Sep; 175(3):642-4. PubMed ID: 27038429
    [No Abstract]   [Full Text] [Related]  

  • 28. Butyrylcholinesterase is present in the human epidermis and is regulated by H2O2: more evidence for oxidative stress in vitiligo.
    Schallreuter KU; Gibbons NC; Zothner C; Elwary SM; Rokos H; Wood JM
    Biochem Biophys Res Commun; 2006 Oct; 349(3):931-8. PubMed ID: 16962996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patchy facial hyperpigmentation.
    Kindem S; Serra-Guillén C; Guillén C
    Actas Dermosifiliogr; 2015 May; 106(4):317-8. PubMed ID: 25267567
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunohistopathological analysis of frizzled-4-positive immature melanocytes from hair follicles of patients with Rhododenol-induced leukoderma.
    Okamura K; Ohe R; Abe Y; Ueki M; Hozumi Y; Tamiya G; Matsunaga K; Yamakawa M; Suzuki T
    J Dermatol Sci; 2015 Nov; 80(2):156-8. PubMed ID: 26277630
    [No Abstract]   [Full Text] [Related]  

  • 31. Activation/deactivation of acetylcholinesterase by H2O2: more evidence for oxidative stress in vitiligo.
    Schallreuter KU; Elwary SM; Gibbons NC; Rokos H; Wood JM
    Biochem Biophys Res Commun; 2004 Mar; 315(2):502-8. PubMed ID: 14766237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study.
    Saraceno R; Nisticò SP; Capriotti E; Chimenti S
    Dermatol Ther; 2009; 22(4):391-4. PubMed ID: 19580584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of possible chemical leukoderma secondary to usage of skin whitening agents.
    Cho M; Otsuka A; Irie H; Kataoka T; Kabashima K
    Eur J Dermatol; 2018 Oct; 28(5):701-702. PubMed ID: 30355541
    [No Abstract]   [Full Text] [Related]  

  • 34. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.
    Parsad D; Kanwar AJ; Kumar B
    J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):175-7. PubMed ID: 16441626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro evidence for epidermal H2O2-mediated oxidative stress in piebaldism.
    Vafaee T; Rokos H; Salem MM; Schallreuter KU
    Exp Dermatol; 2010 Oct; 19(10):883-7. PubMed ID: 19758321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanocytes are not absent in lesional skin of long duration vitiligo.
    Tobin DJ; Swanson NN; Pittelkow MR; Peters EM; Schallreuter KU
    J Pathol; 2000 Aug; 191(4):407-16. PubMed ID: 10918216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skin lightening agents - Use or abuse? - A retrospective analysis of the topical preparations used by melasma patients of darker skin types.
    Kandhari R; Khunger N
    Indian J Dermatol Venereol Leprol; 2013; 79(5):701-2. PubMed ID: 23974587
    [No Abstract]   [Full Text] [Related]  

  • 38. The risk of chemical leucoderma with skin-lightening therapies.
    Odedra S; Yoo J
    Clin Exp Dermatol; 2021 Oct; 46(7):1391-1393. PubMed ID: 34263475
    [No Abstract]   [Full Text] [Related]  

  • 39. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo.
    Kullavanijaya P; Lim HW
    Photodermatol Photoimmunol Photomed; 2004 Oct; 20(5):248-51. PubMed ID: 15379875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood facial vitiligo: how intractable is it?
    Kim SA; Cho S; Kwon SH; Park JT; Na JI; Huh CH; Park KC
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):713-8. PubMed ID: 25174801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.